Emerging drugs for cancer cachexia.
Cachexia is a complex syndrome. The main components of this pathological state are anorexia and metabolic abnormalities such as glucose intolerance, fat depletion and muscle protein catabolism among others. The altered metabolic status generates a high degree of energetic inefficiency that results in weight loss, fatigue and a considerable loss of muscle and, therefore, asthenia. The aim of the present article is to review the different therapeutic approaches and emerging drugs that have been designed to fight and counteract cachexia associated with cancer.
Argilés
Josep M
JM
Universitat de Barcelona, Cancer Research Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Diagonal 645, 08071-Barcelona, Spain. jargiles@ub.edu
López-Soriano
Francisco J
FJ
Busquets
Sílvia
S
D000818:Animals; D019167:Appetite Stimulants / Q000494:pharmacology / Q000627:therapeutic use; D002100:Cachexia / Q000178:diet therapy / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D002986:Clinical Trials as Topic; D015195:Drug Design; D004345:Drug Industry; D004435:Eating / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000378:metabolism; D013329:Structure-Activity Relationship
D019167:Appetite Stimulants